Featured ArticlesHome page featureThe Latest

Acne Vulgaris Treatment Falls Short

Featured Article

Featured Article

Acne Vulgaris Treatment Falls Short

The majority of acne patients are not likely to achieve success according to FDA guidance. Is the FDA guidance too rigorous?

More Acne News

Luciana Nofal

What is the likelihood of treatment success in patients with acne vulgaris?

According the FDA, success is defined as clear or almost clear.  The FDA recommends using the IGA grading scale. The different grades include clear (grade 0), almost clear (grade 1), mild severity (grade 2), moderate severity (grade 3), and severe (grade 4). However, there are many different scales for grading acne severity.

Data from the 2012 to 2016 NAMCS was used to determine the number of medications prescribed for outpatient visits when isotretinoin was prescribed or when isotretinoin was not prescribed and the one and only diagnosis was acne. These surveys were developed and implemented by the National Center of Health Statistics, part of the Center for Disease Control and Prevention (CDC). Results from the survey provide nationally representative yearly estimates of non-hospital-based outpatient healthcare utilization.

This study finds the majority of acne patients are not likely to achieve success according to FDA guidance. The study proposes that the FDA guidance may be too rigorous. An alternative hypothesis is that most acne patients are undertreated.

Further studies should be done to demonstrate a clinically meaningful severity difference, or minimum clinically important difference, in acne severity and these studies may help redefine acne treatment success.

How did the oral and topical medications perform? What drugs were the most efficacious at the end of 12 weeks?

The authors compared 19 oral and topical acne treatments and the results may be surprising. Read the article to find out.

  1. Adapalene and benzoyl peroxide gel 0.1%/2.5%
  2. Adapalene gel 0.1%
  3. Adapalene gel 0.3%
  4. Benzoyl Peroxide gel 2.5%
  5. Clindamycin gel 1.2%
  6. Clindamycin phosphate and benzoyl peroxide gel 1.2%/2.5%
  7. Clindamycin phosphate and tretinoin gel 1.2%/0.025%
  8. Dapsone gel 5%
  9. Dapsone gel 7.5%
  10. Minocycline foam 4%
  11. Tazarotene cream 0.1%
  12. Tazarotene foam 0.1%
  13. Tretinoin lotion 0.05%
  14. Trifarotene cream
  15. Doxycycline calcium tablet
  16. Drospirenone/ethinyl estradiol tablet
  17. Extended release minocycline
  18. Isotretinoin capsule
  19. Sarecycline tablet

 

Acne Vulgaris: The Majority of Patients Do Not Achieve Success According to FDA Guidance
Keshav Patel MS, Katherine Baquerizo Nole MD, Alan Fleischer Jr. MD

You May Also Like

Journal of Drugs in Dermatology JDD Video Abstract Image.

JDD Recent Video Abstract Picks

| Acne, Featured Articles, Latest News, Skincare, The Latest | No Comments
Did You Miss These?   Missed any of our recent Video Abstracts? Catch up now! A Scientific Approach to Defining, Evaluating, and Treating Pre-Aging With a Cosmetic Regimen Containing a…
Journal of Drugs in Dermatology JDD Article About Botulinum Toxin in Hidradenitis Suppurativa: A Systematic Review

Botulinum Toxin in Hidradenitis Suppurativa: A Systematic Review

| Featured Articles, Hidradenitis Suppurativa, Latest News, The Latest | No Comments
Botulinum Toxin for Hidradenitis Suppurativa? Early Evidence Looks Promising Hidradenitis suppurativa  (HS) remains a challenging and often painful condition—one that disproportionately affects women, people of color, and underserved populations. With…
Journal of Drugs in Dermatology JDD Author Spotlight featuring Natalia N. Khosla MD.

July Author Spotlight

| Alopecia, Author Spotlight, Derm Community, Featured Articles, Latest News, The Latest | No Comments
Author Spotlight: Dr. Natalia Neha Khosla on Health Equity, Inflammation, and Innovation in Dermatology July’s JDD Author Spotlight  features Natalia Neha Khosla, MD MSc, author of the July article, “Socioeconomic…

Leave a Reply